10th Sep 2007 17:26
Vernalis PLC10 September 2007 10 September 2007 NOTICE OF INTERIM FINANCIAL RESULTS Vernalis plc (LSE VER) today announces that it will be releasing its interimresults for the six months ended 30 June 2007 on Thursday, 13 September 2007. Vernalis will hold a conference call for analysts at 11am BST. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial Officer Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroyAlex Tweed Lazar Partners LtdGregory Gin +1 212-867-1762 Notes to Editors Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec, Serono and Chiesi: This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC